On December 4, 2025, Oncotelic Therapeutics, Inc. (OTLC) completed entering into subscription agreements with certain accredited investors, issuing 11 units as part of an offering of up to 500 units. The 8-K filing disclosed a total principal amount of $275,000 for the notes issued, with each unit priced at $25,000.

Each unit consists of one note with a $25,000 principal amount bearing 12 percent annual interest, due on the two-year anniversary of the final closing. According to the filing, the notes are convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share.

The offering includes 250,000 warrants per unit to purchase Oncotelic common stock at $0.12 per share or 25,000 warrants to purchase EdgePoint common stock at $1.25 per share. Warrants are exercisable for two years after issuance, according to the SEC filing submitted on December 9, 2025.

Chief Executive Officer Vuong Trieu signed the subscription agreements for Oncotelic Therapeutics, Inc. The offering is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, limiting sales to accredited investors in the United States.